氨酸治疗饮食障碍患者的耐治疗抑郁症:一项比较研究
Elizabeth Wassenaar1, Dan V Blalock2,3,4, Alan Duffy4
1Eating Recovery Center, 8190 E 1st Ave, Denver, CO, 80230, USA. elizabeth.wassenaar@ercpathlight.com.
Journal of eating disorders
|December 10, 2025
概括
胺治疗在改善饮食障碍 (ED) 和抑郁症症状方面没有显著差异,与在更高水平的护理环境中接受标准护理相比. 需要进一步的研究来确认胺.
科学领域:
- 神经科学是一个神经科学.
- 精神病学是一个精神病学.
- 临床心理学 临床心理学
背景情况:
- 患有饮食障碍 (EDs) 的人面临更高的治疗耐药性抑郁症 (TRD) 和治疗耐药性双相情感障碍 (TRBD) 的风险,以及自杀念头和自杀死亡率的增加.
- 对于情绪障碍的传统治疗方法在ED患者中往往效果不佳.
- 胺在治疗TRD,TRBD和急性自杀倾向方面表现有前途,并且在营养不良的ED患者中已经证明了安全性.
研究的目的:
- 这项研究调查了胺在治疗TRD和TRBD的疗效,同时发生ED的患者中.
- 这项研究检查了胺在需要更高水平治疗饮食障碍的人群中的有效性.
主要方法:
- 八十五名进入ED治疗设施的成年人接受了亚麻醉性鼻内胺.
- 一个由85名成年人组成的对照组,主要的人口统计和诊断相匹配,没有接受胺.
- 参与者在入院和出院时填写了饮食障碍检查问卷 (EDE-Q),患者健康问卷-9 (PHQ-9) 和全局焦虑障碍-7 (GAD-7).
主要成果:
- 胺接受者和对照者都显示ED症状,抑郁和焦虑从入院到出院的显著改善.
- 在胺组和对照组之间没有观察到治疗结果的显著差异.
- 接受胺治疗的患者的停留时间明显更长.
结论:
- 在寻求更高水平治疗ED的个体中,胺治疗与抑郁症和ED严重程度的显著降低有关,但不超过对照组.
- 研究结果表明,胺可能是EDS和并发性抑郁症患者的可行治疗选择.
- 需要进一步的研究才能完全确定胺在治疗伴随抑郁症的ED治疗中的有效性.
相关概念视频
Electroconvulsive Therapy
792
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
792
Antidepressant Drugs: MAOIs and Other Agents
770
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
770
Binge Eating Disorders
402
Binge eating disorder is a significant mental health condition characterized by recurrent episodes of excessive food consumption within a short period, accompanied by a perceived loss of control over eating behavior. Unlike occasional overeating, binge eating disorder is marked by distressing emotions such as guilt, shame, and anxiety following binge episodes. The disorder affects individuals across different ages and backgrounds, with profound implications for physical and psychological...
402
Bulimia Nervosa
641
Bulimia nervosa is a complex and severe eating disorder characterized by a cyclical pattern of binge-and-purge eating pattern. It generally involves an episode of binge eating, followed by compensatory behaviors such as vomiting, excessive exercise, laxative use, or fasting, to prevent weight gain. Despite often maintaining a normal weight, individuals with bulimia are intensely preoccupied with their body image and harbor an overwhelming fear of gaining weight. This can contribute to the...
641
Anorexia Nervosa
865
Anorexia nervosa is a complex and severe eating disorder characterized by an intense fear of weight gain, an unrelenting pursuit of thinness, and a distorted body image. It often leads to dangerously low body weight relative to an individual's age and height. This disorder is marked by significant physical and psychological consequences, making it one of the most life-threatening psychiatric illnesses.
Symptoms and Physical Effects
Individuals with anorexia nervosa commonly exhibit extreme...
Symptoms and Physical Effects
Individuals with anorexia nervosa commonly exhibit extreme...
865
Psychosis: Goals of Pharmacotherapy
441
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
441


